Zimmer Biomet (NYSE:ZBH) Price Target Raised to $100.00

Zimmer Biomet (NYSE:ZBH) had its price target increased by Canaccord Genuity Group from $83.00 to $100.00 in a report issued on Monday morning, Marketbeat Ratings reports. The brokerage currently has a hold rating on the medical equipment provider’s stock.

Other analysts have also issued research reports about the company. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a report on Thursday, August 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. UBS Group reiterated a “buy” rating and issued a $120.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. Citizens Jmp cut their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a report on Wednesday, April 29th. Finally, Zacks Research lowered shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $104.42.

Zimmer Biomet Price Performance

NYSE ZBH opened at $97.58 on Monday. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $108.29. The firm has a market capitalization of $18.61 billion, a PE ratio of 23.74, a P/E/G ratio of 3.09 and a beta of 0.45. The company’s 50 day simple moving average is $90.99 and its 200 day simple moving average is $90.38. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, equities research analysts forecast that Zimmer Biomet will post 8.53 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, July 31st. Investors of record on Thursday, June 25th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Thursday, June 25th. Zimmer Biomet’s payout ratio is presently 23.36%.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.28% of the stock is owned by company insiders.

Institutional Trading of Zimmer Biomet

Several institutional investors and hedge funds have recently bought and sold shares of ZBH. Main Management ETF Advisors LLC grew its holdings in Zimmer Biomet by 1.0% during the 4th quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock worth $986,000 after acquiring an additional 112 shares during the last quarter. Citizens National Bank Trust Department raised its stake in shares of Zimmer Biomet by 17.6% in the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 141 shares during the last quarter. LOM Asset Management Ltd raised its stake in shares of Zimmer Biomet by 21.5% in the fourth quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider’s stock worth $75,000 after acquiring an additional 147 shares during the last quarter. Oppenheimer & Co. Inc. lifted its position in shares of Zimmer Biomet by 0.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider’s stock worth $1,831,000 after purchasing an additional 152 shares in the last quarter. Finally, TD Private Client Wealth LLC lifted its position in shares of Zimmer Biomet by 15.3% during the fourth quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider’s stock worth $104,000 after purchasing an additional 153 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.